San Diego, CA, September 1, 2015 – One of every hundred Americans has type 1 diabetes (T1D). Millions of children and adults struggle with this autoimmune disease. Yet, funding has decreased for research to prevent, cure, and better manage the disease. Of the funding available, 97% goes to established scientists. Early-career scientists are often the source of radical new ideas but have difficulty finding money to support them, forcing many to leave the field of diabetes research.
The Diabetes Research Connection (DRC) created a platform which connects donors directly with early-career scientists, enabling them to perform research designed to prevent and cure T1D, minimize its complications, and improve the quality of life for those living with the disease.
Scientists submit their projects to a panel of over 80 leading diabetes experts who review it for innovation, feasibility, value, and achievability. As established scientists, DRC’s panel of experts donates their time and expertise to encourage the next generation of diabetes investigators to push the envelope.
The time from application to funding can be as little as 12 weeks, compared to 18 months for many research grants. In 2015, 100% of research funds go directly to the scientists’ lab. To ensure transparency, each researcher provides updates on their project, posting final outcomes on DRC’s website.
Alberto Hayek, M.D., co-founder and president of the Diabetes Research Connection and world-renowned diabetes expert believes that the lack of funding for early, discovery-stage projects is one of the biggest problems in research. “With DRC, we are giving scientists the resources to test and validate research that departs from conventional thinking, because the opportunity to pursue new paths is when and where breakthroughs occur,” says Hayek.
Dr. Todd Brusko from the University of Florida received $50,000 through DRC to begin working on his project titled, “Can we engineer a patient’s immune cells to stop the autoimmune attack that causes T1D?”
“In six months, my project has made remarkable progress. My lab isolated and expanded a rare population of regulatory T cells (Tregs) to a level that appears to thwart the autoimmune attack when the Tregs are re-infused into type 1 diabetes patients. I teamed up with biomaterial engineers to create nanoparticles which carry the necessary growth factors. Together we found a way to link these particles directly to the surface of the Tregs. My next step is to determine whether these cells are effective at preventing autoimmune disease in animal models,” says Brusko.
Ph.D. candidate, Kristin Mussar, from the University of Washington received $54,000 through DRC to begin working on her project titled, “Creating new insulin-producing cells to repair the damaged pancreas.”
“No other lab in the United States is currently researching macrophages to determine if this type of white blood cell, typically involved in fighting off viruses or colds, may help repair pancreatic beta cells. If successful, my project may lead to finding a molecule or drug that can be given to T1D patients to help them restore their body’s natural ability to produce insulin,” says Mussar.
DRC was established in 2012 by five tireless proponents of diabetes research. Dr. Alberto Hayek, emeritus professor from the University of California and Scientific Director at Scripps/Whittier Diabetes Institute in San Diego; Doctors Nigel Calcutt and Charles King, diabetes research scientists affiliated with the University of California; David Winkler, an attorney, entrepreneur and venture philanthropist who was diagnosed with type 1 diabetes at the age of six, and Amy Adams, a writer and business owner whose son has lived with type 1 diabetes for most of his life.
“As someone who has lived with type 1 diabetes for more than 50 years, and who has other family members and friends who have diabetes, I know firsthand how this disease impacts a person’s life and the lives of those around him or her,” says Winkler.